1 / 27

Maximum concentrations of fluores

Maximum concentrations of fluores cein in rabbit's anterior chamber after one minute of iontophoresis with currents shown or with no current (0 mamp). Each symbol indicates one eye; open circles, 0.03% fluoresce in solution; closed circles, 0.3% fluorescein solution.

ronat
Download Presentation

Maximum concentrations of fluores

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Maximum concentrations of fluores cein in rabbit's anterior chamber after one minute of iontophoresis with currents shown or with no current (0 mamp). Each symbol indicates one eye; open circles, 0.03% fluoresce in solution; closed circles, 0.3% fluorescein solution. A Fresh Look at Iontophoresis – Arch Ophthalmol – Vol 102, Dec 1984

  2. Gentamicin concentrations in rabbit's aqueous humor two hours after simple immersion for ten minutes or iontophoresis at 1 mamp for one minute. A Fresh Look at Iontophoresis – Arch Ophthalmol – Vol 102, Dec 1984

  3. Suggested method of using ionto phoresis to deliver drug from hydrophilic contact lens in which contact is made through cotton-tipped applicator soaked in saline. Electrical circuit is designed to deliver 1 mamp and to diminish switching transients. K indicates kilo Ω A Fresh Look at Iontophoresis – Arch Ophthalmol – Vol 102, Dec 1984

  4. Total radioactivity in acid-soluble fraction of rabbit eye after administration of tritiated vidarabine monophosphate Iontophoresis of vidarabine monophosphate into rabbit eyes. - Invest. Ophthal. Visual Sci. May 1978

  5. Progression of Cytomegalovirus Retinitis in Eyes Affected at Base Line. TREATMENT OF CYTOMEGALOVIRUS RETINITIS WITH A SUSTAINED-RELEASE GANCICLOVIR IMPLANT - Volume 337 Number 2 – Fig 1

  6. Survival among Patients with Cytomegalovirus Retinitis. TREATMENT OF CYTOMEGALOVIRUS RETINITIS WITH A SUSTAINED-RELEASE GANCICLOVIR IMPLANT - Volume 337 Number 2 – Fig 2

  7. Neurotech’s proprietary encapsulated cell therapy. Encapsulated cell implants consist of living cells encapsulated within semipermeable polymer membranes and supportive matrices: (A) longitudinal view of cell-containing implant: (B) intraocular placement of an encapsulated cell implant Intraocular Drug Delivery – Chapter 08, Fig 2

  8. Chamber A contains a diffusant that is full dissolved in A and is at a higher concentration than in chamber B, which is a perfect sink. Diffusion from A to B is driven by the concentration difference between the two chambers. • (B) Chamber A contanins a suspension of a diffusant. As the diffunsant moves to chamber B, the decrease in concentration can be off-set by the dissolution of the suspended particles, which acts to maintain the concentration gradient Intraocular Drug Delivery – Chapter 01, Fig 3

  9. Intra-ocular pressure (mmHg) of rabbit’s eye after instillation of 1% w/v atenolol in solution and in different concentrations of CMC gel A Long Acting Ophthalmic Gel Formulations of Atenolol - Drug Development and Industrial Pharmacy, 33:1192–1198, 2007 – fig 7

  10. Intra-ocular pressure (mmHg) of rabbit’s eye after instillation of 1% w/v atenolol in solution and in different concentrations of sodium alginate gel. A Long Acting Ophthalmic Gel Formulations of Atenolol - Drug Development and Industrial Pharmacy, 33:1192–1198, 2007 – fig 8

  11. Model of drug uptake by the cornea from the tears Clinical pharmacokinetics of the eye – Invest Ophthalmol Vis 21:504-541, 1981

  12. Time course of the concentration changes of the drug in cornea (upper curve) and in the anterior chamber (lower curve) after instillation of 50 Ul of 1% C-befunol in the albino rabbit eye Clinical pharmacokinetics of the eye – Invest Ophthalmol Vis 21:504-541, 1981

  13. Permeability of the epithelial barrier (Kep) of the rabbit cornea to various drugs Clinical pharmacokinetics of the eye – Invest Ophthalmol Vis 21:504-541, 1981

  14. Pharmacokinetic coefficients in the human eye for various drug, calculated from actual measurements of aqueous concentrations Clinical pharmacokinetics of the eye – Invest Ophthalmol Vis 21:504-541, 1981

  15. Relationships between the peak aqueous concentration and the loss rate in the tears Clinical pharmacokinetics of the eye – Invest Ophthalmol Vis 21:504-541, 1981

  16. Relationship between the relative bioavailability and the drop size of 0.5% pilocarpine solution. Solid lines, Probable range of the mean. Clinical pharmacokinetics of the eye – Invest Ophthalmol Vis 21:504-541, 1981

  17. Time course of the response parameter after instillation of 0.5% pilocarpine solution (•), 0.5% pilocarpine in 0.5% HPMC solution (o), and after application of 100 mg of 0.5% pilocarpine ointment (▲). Clinical pharmacokinetics of the eye – Invest Ophthalmol Vis 21:504-541, 1981

  18. Relationship between the relative bioavailability and the viscosity of the HPMC solution containing 0.5% pilocarpine. Solid lines, Probable range of the mean. Clinical pharmacokinetics of the eye – Invest Ophthalmol Vis 21:504-541, 1981

  19. Relative bioavailability and the degree of tear film saturation. Clinical pharmacokinetics of the eye – Invest Ophthalmol Vis 21:504-541, 1981

  20. Time course of the response parameter after instillation of 0.5% pilocarpine solution (•), instillation of 0.5% pilocarpine in 0.5% HPMC solution (o), and after 1 hr wear of the soft contact lens (▲) presoaked in 0.02% pilocarpine solution for 25 min. Clinical pharmacokinetics of the eye – Invest Ophthalmol Vis 21:504-541, 1981

  21. Time course of the response parameter after instillation of 0.5% pilocarpine in the presence (▲) and absence (∆) of soft contact lens in the eye. Left, Increased bioavailability; right, decreased bioavailability by the presence of soft contact lens Clinical pharmacokinetics of the eye – Invest Ophthalmol Vis 21:504-541, 1981

  22. Pharmacokinetic coefficients of cycloplegic responses Clinical pharmacokinetics of the eye – Invest Ophthalmol Vis 21:504-541, 1981

  23. Schematic drawing of the ocular structures and the principal routes by which active ingredients pass into the circulation system Systemic adverse effects of topical ocular treatments - Presse Med 2005; 34: 589-95

  24. Transfer of a ionizable molecule through the cornea Systemic adverse effects of topical ocular treatments - Presse Med 2005; 34: 589-95

  25. Cost Analysis of Glaucoma Medications: A 3-Year R - Journal of Glaucoma 11:354–358 / 2000

  26. Yearly cost per patient for selected glaucoma medications Cost Analysis of Glaucoma Medications: A 3-Year R - Journal of Glaucoma 11:354–358 / 2000

More Related